New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:20 EDTVRTXVertex focused on programs in CF, hepatitis C and autoimmune diseases in 2013
Vertex’s key strategies and business priorities include: Focusing investment on key development programs for: Cystic Fibrosis, CF: Vertex’s CF strategy is to provide benefit to as many CF patients as possible. Hepatitis C: Vertex’s strategy in hepatitis C is to develop new all-oral treatment regimens of 12 weeks or less in duration with a goal of providing a high viral cure rate and improved tolerability. In 2013, Autoimmune Diseases: Vertex’s strategy in autoimmune diseases is to maximize the value of VX-509 across multiple autoimmune diseases globally. The company will evaluate collaborative opportunities that provide funding and capabilities to broaden and accelerate global development of VX-509. Autoimmune Diseases: Maximizing revenues and cash flow from the appropriate use of INCIVEK®(telaprevir) and KALYDECO in the U.S. and Canada and from the growth of KALYDECO in Europe and other countries 4. Maintaining financial strength to support future growth and shareholder returns.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
16:49 EDTVRTXVertex: FDA Advisory Committee recommends approval of KALYDECO
Vertex Pharmaceuticals announced that the U.S. Food and Drug Administration’s Pulmonary Allergy Drugs Advisory Committee voted 13-2 to recommend approval of KALYDECO in people with cystic fibrosis ages 6 and older who have the R117H mutation in the cystic fibrosis transmembrane regulatory gene, which is the indication being reviewed by the FDA.
15:25 EDTVRTXPanel backs approval for Vertex CF drug in R117H mutation, Bloomberg says
Subscribe for More Information
15:18 EDTVRTXPanel votes Vertex CF drug safe, works for R117H mutation, Bloomberg reports
Subscribe for More Information
07:11 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committe to hold a meeting
Subscribe for More Information
October 17, 2014
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
October 14, 2014
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
October 13, 2014
10:08 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:23 EDTVRTXVertex price target raised to $131 from $119 at RW Baird
Subscribe for More Information
05:35 EDTVRTXVertex upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Vertex Pharmaceuticals to Overweight citing likely approval of the company's Kalydeco plus lumacaftor combination next year. Piper expects Vertex's Cystic Fibrosis sales to grow to $3.1B in 2016 and raised its price target for shares to $125 from $87.50.
October 10, 2014
08:24 EDTVRTXVertex price target raised to $117 from $109 at Maxim
Maxim raised its price target for Vertex shares to $117 after the company gave an update at the Cystic Fibrosis Conference. The form keeps a Buy rating on the stock.
October 9, 2014
09:33 EDTVRTXVertex says VX-661 Phase 2 study fully enrolled
Subscribe for More Information
07:22 EDTVRTXCystic Fibrosis Foundation to hold a conference
Subscribe for More Information
October 7, 2014
07:46 EDTVRTXPTC Therapeutics weakness a buying opportunity, says Oppenheimer
Oppenheimer believes that the Street is underestimating the opportunity for PTC Therapeutics' (PTCT) Translarna in the most severe patients with Cystic fibrosis. The firm thinks the drug is not competitive with, and can potentially be complemented by, therapies from Vertex (VRTX). Oppenheimer views the weakness in PTC as a buying opportunity and keeps its Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use